CY1121534T1 - Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιας - Google Patents
Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιαςInfo
- Publication number
- CY1121534T1 CY1121534T1 CY20191100356T CY191100356T CY1121534T1 CY 1121534 T1 CY1121534 T1 CY 1121534T1 CY 20191100356 T CY20191100356 T CY 20191100356T CY 191100356 T CY191100356 T CY 191100356T CY 1121534 T1 CY1121534 T1 CY 1121534T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diabetes
- treatment
- obesity
- dihydrobenzofurane
- compounds used
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014025832 | 2014-02-13 | ||
| PCT/JP2015/000639 WO2015122187A1 (en) | 2014-02-13 | 2015-02-12 | Fused heterocyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121534T1 true CY1121534T1 (el) | 2020-05-29 |
Family
ID=52589729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100356T CY1121534T1 (el) | 2014-02-13 | 2019-03-27 | Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιας |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US9346776B2 (uk) |
| EP (1) | EP3105213B1 (uk) |
| JP (2) | JP6383427B2 (uk) |
| KR (1) | KR102378454B1 (uk) |
| CN (1) | CN105980370B (uk) |
| AR (1) | AR099400A1 (uk) |
| AU (1) | AU2015216438B2 (uk) |
| BR (1) | BR112016018455B1 (uk) |
| CA (1) | CA2938191C (uk) |
| CL (1) | CL2016001911A1 (uk) |
| CR (1) | CR20160367A (uk) |
| CY (1) | CY1121534T1 (uk) |
| DK (1) | DK3105213T3 (uk) |
| DO (1) | DOP2016000206A (uk) |
| EA (1) | EA032201B1 (uk) |
| EC (1) | ECSP16067137A (uk) |
| ES (1) | ES2717113T3 (uk) |
| HR (1) | HRP20190369T1 (uk) |
| HU (1) | HUE042709T2 (uk) |
| IL (1) | IL246838B (uk) |
| JO (1) | JO3472B1 (uk) |
| LT (1) | LT3105213T (uk) |
| MA (1) | MA39246A1 (uk) |
| ME (1) | ME03422B (uk) |
| MX (1) | MX368392B (uk) |
| MY (1) | MY173607A (uk) |
| NZ (1) | NZ722035A (uk) |
| PE (1) | PE20161243A1 (uk) |
| PH (1) | PH12016501582B1 (uk) |
| PL (1) | PL3105213T3 (uk) |
| PT (1) | PT3105213T (uk) |
| RS (1) | RS58498B1 (uk) |
| SG (1) | SG11201605654QA (uk) |
| SI (1) | SI3105213T1 (uk) |
| TR (1) | TR201903892T4 (uk) |
| TW (1) | TWI669297B (uk) |
| UA (1) | UA118280C2 (uk) |
| UY (1) | UY35994A (uk) |
| WO (1) | WO2015122187A1 (uk) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA118668C2 (uk) * | 2013-03-13 | 2019-02-25 | Такеда Фармасьютікал Компані Лімітед | Сполука складного ефіру гуанідинобензойної кислоти |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
| SI3105226T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot zaviralci LSD1 |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| JP2018080109A (ja) * | 2015-03-16 | 2018-05-24 | 武田薬品工業株式会社 | 治療剤 |
| WO2016158788A1 (ja) * | 2015-03-27 | 2016-10-06 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
| CN110402244B (zh) | 2015-08-12 | 2023-02-03 | 因赛特公司 | Lsd1抑制剂的盐 |
| KR20200075867A (ko) | 2017-11-02 | 2020-06-26 | 우베 고산 가부시키가이샤 | 단백 분해 효소의 쌍두형 저해제 |
| BR112020022790A2 (pt) | 2018-05-09 | 2021-02-02 | Lg Chem, Ltd | novo composto que exibe atividade inibitória de enteropeptidase |
| EP3650440A4 (en) | 2018-08-27 | 2020-11-25 | Scohia Pharma, Inc. | BENZOIC ESTER COMPOUND |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| US20220281866A1 (en) | 2019-07-19 | 2022-09-08 | Janssen Pharmaceutica Nv | 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| WO2021166899A1 (ja) * | 2020-02-17 | 2021-08-26 | 宇部興産株式会社 | インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤 |
| CN111544599B (zh) * | 2020-07-10 | 2020-12-01 | 有术肌肤管理(深圳)有限公司 | 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途 |
| CN111803652B (zh) * | 2020-08-04 | 2021-09-14 | 南通康是美生物科技有限公司 | 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5289640A (en) | 1976-01-21 | 1977-07-27 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives |
| AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| JPS5753454A (en) | 1980-09-16 | 1982-03-30 | Torii Yakuhin Kk | Guanidinobenzoate and anticomplementary agent |
| US5116985A (en) | 1989-12-28 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Isoquinoline derivatives and salts thereof |
| JP2886586B2 (ja) | 1989-12-28 | 1999-04-26 | 雪印乳業株式会社 | 新規グアニジノ安息香酸誘導体及びその酸付加塩 |
| JPH0446148A (ja) | 1990-06-08 | 1992-02-17 | Asahi Chem Ind Co Ltd | ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
| JPH06192085A (ja) | 1992-08-31 | 1994-07-12 | Yuji Inada | ダニアレルギー治療剤 |
| EP0673924A4 (en) | 1992-12-10 | 1996-04-24 | Teikoku Chem Ind Co Ltd | PROPRIONIC ACID DERIVATIVE. |
| JPH0753500A (ja) | 1993-08-16 | 1995-02-28 | Sanwa Kagaku Kenkyusho Co Ltd | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 |
| JPH0848664A (ja) | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
| WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| JPH09124571A (ja) | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
| KR20000005312A (ko) | 1996-04-10 | 2000-01-25 | 오노 야꾸힝 고교 가부시키가이샤 | 트립타아제 억제제 및 신규 구아니디노 유도체 |
| JPH10101556A (ja) | 1996-09-27 | 1998-04-21 | Ono Pharmaceut Co Ltd | ファクターｄ阻害剤 |
| JPH10251239A (ja) | 1997-03-14 | 1998-09-22 | Mochida Pharmaceut Co Ltd | 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体 |
| JPH10306025A (ja) | 1997-05-07 | 1998-11-17 | Touin Yokohama Univ | 花粉プロテアーゼ阻害剤 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| MXPA05004505A (es) | 2002-11-01 | 2005-07-26 | Takeda Pharmaceutical | Agente para prevenir o tratar la neuropatia. |
| EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
| CA2507026A1 (en) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, their production and use |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
| US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
| US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
| EP1697339A1 (en) | 2003-12-25 | 2006-09-06 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| JP4855777B2 (ja) | 2003-12-26 | 2012-01-18 | 武田薬品工業株式会社 | フェニルプロパン酸誘導体 |
| EP1726580A4 (en) | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | AMINOPHNYLPROPANO ACID DERIVATIVE |
| EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| WO2006057152A1 (ja) | 2004-11-08 | 2006-06-01 | Ono Pharmaceutical Co., Ltd. | タンパク質分解酵素阻害化合物からなる糖尿病治療剤 |
| CA2588087A1 (en) | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
| EP1811865B1 (en) | 2004-11-26 | 2008-07-16 | N.V. Nutricia | Infant nutrition with protease inhibitor |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| JP2006348023A (ja) * | 2005-05-17 | 2006-12-28 | Santen Pharmaceut Co Ltd | アミン誘導体を有効成分として含む血管新生阻害剤 |
| WO2007013689A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | シクロプロパンカルボン酸化合物 |
| JPWO2007013694A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | フェノキシアルカン酸化合物 |
| RU2008108984A (ru) | 2005-08-10 | 2009-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Терапевтический агент от диабета |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007208495A1 (en) * | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Hydroxyalkylarylamide derivatives |
| PE20080993A1 (es) | 2006-06-27 | 2008-10-06 | Takeda Pharmaceutical | Compuestos ciclicos fusionados como moduladores del receptor gpr40 |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| BRPI0717722A2 (pt) | 2006-10-19 | 2013-10-29 | Takeda Pharmaceutical | Composto ou um sal do mesmo, pró-droga, ativador de glicoquinase, agente farmacêutico, métodos para ativar uma glicoquinase em um mamífero e para a profilaxia ou o tratamento de diabetes ou obesidade em um mamífero, e, uso do composto ou uma pró-droga do mesmo |
| US20100016396A1 (en) | 2007-01-29 | 2010-01-21 | Hiroshi Imoto | Pyrazole compound |
| CA2677736A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| DK2225261T3 (en) | 2007-12-03 | 2016-06-06 | Obe Therapy Biotechnology | Borpeptidinhibitorer of enteropeptidase and their uses in the treatment of obesity, obesity and / or disorders associated with abnormal lipid metabolism |
| DK2511271T3 (en) | 2009-12-07 | 2015-03-23 | Ajinomoto Kk | HETEROARYL CARBOXYLIC ACID RESIDENT. |
| WO2012169579A1 (ja) | 2011-06-07 | 2012-12-13 | 味の素株式会社 | ヘテロ環カルボン酸エステル誘導体 |
| CA2848561C (en) | 2011-09-15 | 2019-04-02 | Astellas Pharma Inc. | Guanidinobenzoic acid compound |
| CN108904810A (zh) | 2012-01-03 | 2018-11-30 | 奥拉姆德有限公司 | 治疗糖尿病的方法和组合物 |
| US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| WO2014106846A2 (en) | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| EA201591614A1 (ru) | 2013-03-08 | 2015-12-30 | Эмджен Инк. | Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения |
| UA118668C2 (uk) | 2013-03-13 | 2019-02-25 | Такеда Фармасьютікал Компані Лімітед | Сполука складного ефіру гуанідинобензойної кислоти |
| ES2773250T3 (es) | 2013-06-21 | 2020-07-10 | Myokardia Inc | Compuestos de pirimidindiona contra afecciones cardíacas |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| SI3105226T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot zaviralci LSD1 |
-
2015
- 2015-02-11 US US14/619,489 patent/US9346776B2/en active Active
- 2015-02-12 SG SG11201605654QA patent/SG11201605654QA/en unknown
- 2015-02-12 SI SI201530626T patent/SI3105213T1/sl unknown
- 2015-02-12 PT PT15706546T patent/PT3105213T/pt unknown
- 2015-02-12 CR CR20160367A patent/CR20160367A/es unknown
- 2015-02-12 CA CA2938191A patent/CA2938191C/en active Active
- 2015-02-12 WO PCT/JP2015/000639 patent/WO2015122187A1/en active Application Filing
- 2015-02-12 ES ES15706546T patent/ES2717113T3/es active Active
- 2015-02-12 TW TW104104693A patent/TWI669297B/zh active
- 2015-02-12 EA EA201691619A patent/EA032201B1/ru not_active IP Right Cessation
- 2015-02-12 CN CN201580007800.9A patent/CN105980370B/zh active Active
- 2015-02-12 HU HUE15706546A patent/HUE042709T2/hu unknown
- 2015-02-12 KR KR1020167025277A patent/KR102378454B1/ko active IP Right Grant
- 2015-02-12 RS RS20190324A patent/RS58498B1/sr unknown
- 2015-02-12 NZ NZ722035A patent/NZ722035A/en unknown
- 2015-02-12 TR TR2019/03892T patent/TR201903892T4/tr unknown
- 2015-02-12 AR ARP150100411A patent/AR099400A1/es active IP Right Grant
- 2015-02-12 PL PL15706546T patent/PL3105213T3/pl unknown
- 2015-02-12 MX MX2016010559A patent/MX368392B/es active IP Right Grant
- 2015-02-12 LT LTEP15706546.7T patent/LT3105213T/lt unknown
- 2015-02-12 JO JOP/2015/0028A patent/JO3472B1/ar active
- 2015-02-12 BR BR112016018455-6A patent/BR112016018455B1/pt active IP Right Grant
- 2015-02-12 US US15/117,538 patent/US9969705B2/en active Active
- 2015-02-12 AU AU2015216438A patent/AU2015216438B2/en active Active
- 2015-02-12 DK DK15706546.7T patent/DK3105213T3/en active
- 2015-02-12 UY UY0001035994A patent/UY35994A/es not_active Application Discontinuation
- 2015-02-12 MA MA39246A patent/MA39246A1/fr unknown
- 2015-02-12 EP EP15706546.7A patent/EP3105213B1/en active Active
- 2015-02-12 ME MEP-2019-89A patent/ME03422B/me unknown
- 2015-02-12 MY MYPI2016702925A patent/MY173607A/en unknown
- 2015-02-12 PE PE2016001239A patent/PE20161243A1/es unknown
- 2015-02-12 JP JP2016550664A patent/JP6383427B2/ja active Active
- 2015-12-02 UA UAA201609351A patent/UA118280C2/uk unknown
-
2016
- 2016-07-19 IL IL246838A patent/IL246838B/en active IP Right Grant
- 2016-07-28 CL CL2016001911A patent/CL2016001911A1/es unknown
- 2016-08-10 PH PH12016501582A patent/PH12016501582B1/en unknown
- 2016-08-11 DO DO2016000206A patent/DOP2016000206A/es unknown
- 2016-08-11 EC ECIEPI201667137A patent/ECSP16067137A/es unknown
-
2018
- 2018-08-03 JP JP2018146459A patent/JP6529649B2/ja active Active
-
2019
- 2019-02-26 HR HRP20190369TT patent/HRP20190369T1/hr unknown
- 2019-03-27 CY CY20191100356T patent/CY1121534T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121534T1 (el) | Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιας | |
| CY1124790T1 (el) | Ενωση πεπτιδιου | |
| PH12016501614A1 (en) | Heterocyclic compound | |
| CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
| DK3192451T3 (da) | Medicinsk krog | |
| DK3474802T3 (da) | Medicinsk forbinding | |
| CY1123842T1 (el) | Ετεροαρυλικες ενωσεις για τη θεραπευτικη αντιμετωπιση οφθαλμικων νοσων | |
| CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
| CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
| BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
| CY1122971T1 (el) | Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων | |
| IT201700051909A1 (it) | Calandra perfezionata | |
| CY1120573T1 (el) | Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης | |
| CY1121279T1 (el) | Ετεροκυκλικη ενωση | |
| DK3191170T3 (da) | Plaster, der kan frembringe mikrostrømme | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| UY36286A (es) | Tratamientos médicos basados en anamorelina | |
| IT201700025175A1 (it) | Ago catetere di sicurezza perfezionato | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| DOP2017000001A (es) | Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer | |
| ITUA20162794A1 (it) | Impianto per avanzamento della cresta tibiale. | |
| IT201700090817A1 (it) | Plantare perfezionato. | |
| ES1189733Y (es) | Calzado perfeccionado | |
| UA37478S (uk) | Шприц медичний | |
| IT201700060894U1 (it) | Soletta perfezionata. |